Electromedical Technologies

Electromedical Technologies ROCE

The Return on Capital Employed (ROCE) of Electromedical Technologies (EMED) as of Nov 11, 2026 is 28.11 %. In the previous year, Return on Capital Employed (ROCE) was 27.74 % — a change of 1.34% (higher).

ROCE

28.11 %

YoY

1.34%

Last updated:

In 2025, Electromedical Technologies's return on capital employed (ROCE) was 28.11 %, a 1.34% increase from the 27.74 % ROCE in the previous year.

The Electromedical Technologies ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
13.62 USD
Jan 1, 2019
76.39 USD
Jan 1, 2020
240.15 USD
Jan 1, 2021
525.99 USD
Jan 1, 2022
72.20 USD
Jan 1, 2023
71.88 USD
Jan 1, 2024
27.74 USD
Jan 1, 2025
28.11 USD
The Electromedical Technologies ROCE history
YEARROCEYoY
28.11 %+1.34%
27.74 %-61.41%
71.88 %-0.45%
72.20 %-86.27%
525.99 %+119.02%
240.15 %+214.39%
76.39 %+460.65%
13.62 %-74.35%
53.11 %-40.90%
89.86 %-77.50%
399.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Electromedical Technologies Stock analysis

What does Electromedical Technologies do? Electromedical Technologies, Inc. generates revenue through the sale of medical devices for pain management, specifically targeting consumers and healthcare professionals. The company's primary products include WellnessPro Plus, WellnessPro POD, and Wellness ION Pen, which utilize bioelectronics and electrical impulses to alleviate pain without drugs. WellnessPro Plus functions as a prescription device that mimics the body's electric signals with micro-current stimulation, while the Wellness ION Pen delivers targeted frequency stimulation via interferential cold laser technology. These products are designed for both consumer and professional use in chronic and acute pain relief. The company focuses on developing electronic medicine solutions that combine micro-stimulation with expanded wavelength capabilities, particularly through the Wellness ION Pen, which is intended for over-the-counter sales. WellnessPro POD is part of the product lineup but lacks detailed description in the business description. The target segments are consumers seeking non-drug pain relief and healthcare professionals who prescribe or recommend these devices for pain management. Electromedical Technologies, Inc. markets its products under the WellnessPro and Wellness ION Pen brand names, emphasizing their unique bioelectronics approach. The company's revenue streams are derived from direct sales of these devices, with WellnessPro Plus positioned as an intelligent therapy device for both home and clinical use. The Wellness ION Pen's over-the-counter availability expands its market reach to general consumers who prefer non-prescription pain management solutions. Electromedical Technologies is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Electromedical Technologies's Return on Capital Employed (ROCE)

Electromedical Technologies's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Electromedical Technologies's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Electromedical Technologies's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Electromedical Technologies’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Electromedical Technologies stock

Return on Capital Employed (ROCE) of Electromedical Technologies is 28.11 % in 2025.

Return on Capital Employed (ROCE) of Electromedical Technologies changed from 27.74 % to 28.11 %, representing a 1.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Electromedical Technologies since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Electromedical Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Electromedical Technologies

All Key Metrics — Electromedical Technologies